20151839

Source:http://linkedlifedata.com/resource/pubmed/id/20151839

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019704, umls-concept:C0021311, umls-concept:C0087111, umls-concept:C0205195, umls-concept:C0674428, umls-concept:C0681850, umls-concept:C1550501, umls-concept:C1667052, umls-concept:C1706203, umls-concept:C2349001, umls-concept:C2697811
pubmed:issue	6
pubmed:dateCreated	2010-2-22
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00098293
pubmed:abstractText	The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20151839-20151843
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0413675
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Retroviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzoxazines, http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanes, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5, http://linkedlifedata.com/resource/pubmed/chemical/Triazoles, http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine, http://linkedlifedata.com/resource/pubmed/chemical/efavirenz, http://linkedlifedata.com/resource/pubmed/chemical/maraviroc
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1537-6613
pubmed:author	pubmed-author:ClumeckNathanN, pubmed-author:CoakleyEoinE, pubmed-author:CooperDavid ADA, pubmed-author:DejesusEdwinE, pubmed-author:GoodrichJamesJ, pubmed-author:HackmanFrancesF, pubmed-author:HeeraJayvantJ, pubmed-author:HorbanAndrzejA, pubmed-author:IvePrudenceP, pubmed-author:MayerHowardH, pubmed-author:MingroneHoracioH, pubmed-author:MohapiLeratoL, pubmed-author:ReevesJacqueline DJD, pubmed-author:Reyes-TeranGustavoG, pubmed-author:SaagMichaelM, pubmed-author:SullivanJohnJ, pubmed-author:TawadrousMargaretM, pubmed-author:TingNaiteeN, pubmed-author:Van Der RystElnaE, pubmed-author:WalmsleySharonS, pubmed-author:WestbyMikeM
pubmed:issnType	Electronic
pubmed:day	15
pubmed:volume	201
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	803-13
pubmed:dateRevised	2010-5-17
pubmed:meshHeading	pubmed-meshheading:20151839-Adolescent, pubmed-meshheading:20151839-Adult, pubmed-meshheading:20151839-Aged, pubmed-meshheading:20151839-Anti-HIV Agents, pubmed-meshheading:20151839-Anti-Retroviral Agents, pubmed-meshheading:20151839-Antiviral Agents, pubmed-meshheading:20151839-Benzoxazines, pubmed-meshheading:20151839-Cyclohexanes, pubmed-meshheading:20151839-Double-Blind Method, pubmed-meshheading:20151839-Drug Combinations, pubmed-meshheading:20151839-Drug Resistance, Viral, pubmed-meshheading:20151839-Drug Therapy, Combination, pubmed-meshheading:20151839-Female, pubmed-meshheading:20151839-HIV Infections, pubmed-meshheading:20151839-HIV-1, pubmed-meshheading:20151839-Humans, pubmed-meshheading:20151839-Lamivudine, pubmed-meshheading:20151839-Male, pubmed-meshheading:20151839-Middle Aged, pubmed-meshheading:20151839-Receptors, CCR5, pubmed-meshheading:20151839-Treatment Outcome, pubmed-meshheading:20151839-Triazoles, pubmed-meshheading:20151839-Viral Load, pubmed-meshheading:20151839-Viral Tropism, pubmed-meshheading:20151839-Young Adult, pubmed-meshheading:20151839-Zidovudine
pubmed:year	2010
pubmed:articleTitle	Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
pubmed:affiliation	University of New South Wales, Sydney, Australia.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase III